The necessity and quandaries of dengue vaccine development.
about
Improving dengue virus capture rates in humans and vectors in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance strategyDengue vaccine: a valuable asset for the futureVirus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesRole of microparticles in dengue virus infection and its impact on medical intervention strategiesTrends in clinical trials of dengue vaccineRecombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.Dengue human infection model: introduction.Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated VaccineSafety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.Sculpting humoral immunity through dengue vaccination to enhance protective immunityCross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice.A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.Treatment of dengue fever.Challenges in reducing dengue burden; diagnostics, control measures and vaccines.Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop.Vaccination for the expatriate and long-term traveler.Recent progress in dengue vaccine development.Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies.An in vitro bioassay for the quantitative evaluation of mosquito repellents against Stegomyia aegypti (=Aedes aegypti) mosquitoes using a novel cocktail meal.Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo.Dengue-Virus-Infektionen
P2860
Q26314599-461D579C-BB22-4AC5-8874-AF0C4040B418Q26314686-4E6C0C4F-8AD8-4363-AF6A-D9A8728F21E6Q26314715-480908E6-603F-4D2A-B8A8-5B52661680C3Q26860307-5573F0C1-48B2-4FFE-A397-9E392A9EAA5EQ28074355-C80ED5CB-7C8E-4934-9B43-79B124AF8775Q30395028-BB88BBAA-A764-4B84-9668-44738C624030Q33724565-ACB4278D-3EC9-46F3-B2A9-EC6707C74BC7Q34297640-CE88F97C-3289-4FF9-B49B-2E4BF235CF25Q34746139-FD759BA8-DF1A-4463-AF5A-3FC840CCCB33Q35976650-BCFC0112-F42C-464B-A73B-509AFBFE3816Q36026210-A625518E-2165-4864-BD57-CC2DEC404A3FQ36382589-89628A1B-E74A-410A-9655-D71DAABFAA3EQ36511979-10ADE2DE-DE23-44E4-82B3-170E78C404B7Q36523070-E3AB5F40-972E-422D-AFF9-452DB003CB5EQ38032553-6D4A5613-99D4-48E9-8FC5-E879D3178B8AQ38140035-832F57E2-6020-44D7-8CFE-39F5B5B28F28Q38202176-D5C729CC-CB55-4D8A-A2C6-B9ECEF69443CQ38208436-830BC45A-9BFD-420A-9BF3-252C8363A510Q38303232-80F76247-A4A9-454E-A567-713D79FD3317Q40136145-05CDBDF2-7F73-44AC-B6AE-59B985BD186EQ42977513-6FBE7B16-5666-4353-BBA3-CE0F6082D015Q47549097-E288FAC6-7337-4F1E-B682-3E3914609E9EQ55109773-D8FC1041-60D0-40BB-9195-7FE92831FDB0
P2860
The necessity and quandaries of dengue vaccine development.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The necessity and quandaries of dengue vaccine development.
@en
The necessity and quandaries of dengue vaccine development.
@nl
type
label
The necessity and quandaries of dengue vaccine development.
@en
The necessity and quandaries of dengue vaccine development.
@nl
prefLabel
The necessity and quandaries of dengue vaccine development.
@en
The necessity and quandaries of dengue vaccine development.
@nl
P2860
P356
P1476
The necessity and quandaries of dengue vaccine development.
@en
P2093
Stephen J Thomas
P2860
P304
P356
10.1093/INFDIS/JIQ060
P407
P577
2011-02-01T00:00:00Z